Trial Profile

Thorough QT study to evaluate the effect of amifampridine on cardiac repolarisation in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Sep 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amifampridine (Primary)
Indications Lambert-Eaton myasthenic syndrome
Focus Adverse reactions

Most Recent Events

07 Apr 2014 New trial record
08 Jan 2014 Primary endpoint 'QT-interval' has been met, according to Catalyst Pharmaceutical Partners media release.
08 Jan 2014 Positive safety results reported in Catalyst Pharmaceutical Partners media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com